Overview of the Top 20 Generics Companies in the World

Click:338  Update time：2020-12-16  【Close】

The 2019 Global 500 list has been released, and Chinese companies have made remarkable achievements. There are 129 Chinese companies on the list, the most in the world. The United States, the "ever-victorious army", has 121 companies on the list, which has been overtaken by China. Japan is in third place with 52 companies, putting it far behind the US and China.

According to the list data statistics,A total of 20 pharmaceutical companies were listed, including renowned chain leaders such as Macon, CVS health, Miguel Bergen, cardeno and Warburg; there were 11 traditional pharmaceutical companies listed, including two Chinese companies, China Huarun Co. Ltd. ranked 80th, rising six times in the previous year; China Pharmaceutical Group ranked 194, rising 25 times in the previous year.The contribution of generics to the performance of pharmaceutical chains or traditional pharmaceutical businesses is still considerable, and while R & D innovative medicines are certainly encouraging and Chonging, the market supply of generics is only the cornerstone to sustain the vast majority of health market demands. This article presents a combed out based on the global sales share of generic companies in 2018 by enumerating the top twenty big players in the generic drug field, the size of the patient population in the health care settings and services they cover is 1.45 billion people in mainland China and also hopes that readers will move through top20 taking some inspiration from the profile of generic pharmaceutical companies, the size, strength, and scope of activities of the Chinese generic industry are still very limited, and there is still much room for growth. The scale of the global generic drug market continues to expand and maintain rapid growth, and its accessibility and pharmacoeconomic advantages are always needed in the market. Generic drugs are the imitation of an approved small molecule drug that has the same active ingredients, dosage form, safety, dosage, route of administration, quality, indications, etc., as the original product.

Generic drug revenue: $690 million
Total number of employees: 7820
Founding year: 1980
Headquarters: Mumbai, India
Market capitalization: $51800 million

Stock Exchange: NSE, India
Piramal healthcare is a global pharmaceutical company offering therapeutics focused on the central nervous system, cardiovascular, anti infective and anti diabetic.In 2018, prime launched desflurane as an inhaled anesthetic generic.In addition, Piramal received 781 generic drug registration applications approved by the US FDA in cumulative terms in 2018.In 2018, Chinese pharmaceutical companies received a total of 99 anda keys at the U.S. FDA, with 80 anda keys approved and 19 tentatively approved.Firm 2019, China Pharmaceutical has FDA approved andas with 92 application numbers, including 76 for prescription drugs, 14 for tentative approval, 1 for over-the-counter drugs, and 1 for withdrawal, involving 28 Chinese pharmaceutical firms.

Generic drug revenue: $90bn
Total number of employees: 3700
Founding year: 1867
Headquarters: Surrey, UK
Market capitalization: $2.88 billion

      
Stock exchanges: the New York Institute
Mallinckrodt is a global pharmaceutical company dedicated to the development and production of therapeutics in a wide range of therapeutic areas, including neuropathy, rheumatism, kidney, lung and Ophthalmology, immunotherapy and neonatal respiratory critical care treatment, and pain medication, with special therapeutic areas pipelines having autoimmune and rare diseases.

Generic drug revenue: $110m
Total number of employees: 2910
Founding year: 1997
Headquarters: Dublin, Ireland
Market capitalization: $1.0 billion
   
Stock Exchange: nadak
Endo international is an Irish based global pharmaceutical company focused on generic and brand-name drugs in therapeutic areas including endocrinology, medico beauty, orthopedics, urology and male health.Endo's percocet (oxycodone / acetaminophen), an opioid analgesic approved for the treatment of moderate to moderately severe pain, generated $120 million in sales worldwide.This year's pain treatment with opioids caused a public opinion crisis in the United States, thousands of patients have become addicted to drugs such as vicodine, percocet, and oshcontindine, and public opinion fermentation has severely impacted the company's stock price.

Generic drug revenue: $1100 million
Total number of employees: 13598
Founding year: 1959
Headquarters: Ahmedabad, India
Market capitalization: $4.05 billion

Stock Exchange: NSE, India
Torrent Pharma is a pharmaceutical company dedicated to the development of therapies for cardiovascular, central nervous system, GI, vitamin mineral nutraceutical (VMN) and women's health care.The company also focuses on diabetes, pain therapy, gynaecology, oncology and anti infective areas.In January 2018, the company acquired bio Pharm to expand its manufacturing and R & D business strength in the United States.

Generic drug revenue: $1.43 billion
Total number of employees: 12000
Founding year: 1977
Headquarters: Mumbai, India
Market capitalization: $147 million
        
Stock Exchange: NSE, India
Glenmark is a global pharmaceutical company focused on generic, specialist, and OTC markets, across therapeutic areas such as dermatology, respiratory, and oncology, including heart disease, diabetes, and oral contraceptives.In 2018, the company received 25 anda approvals, 20 final approvals, and 5 provisional approvals.Glenmark's colesevelam hydrochloride tablets are the first generic drug to be supplied as an oral suspension.The generic drug product line of glenmark covers 152 generic drug products approved for sale in the United States.

Generic drug revenue: $1.66 billion
Total number of employees: 6000
Founding year: 2002
Headquarters: NJ, USA
Market capitalization: $1.04 billion

Stock exchanges: the New York Institute
Amnesal pharmaceuticals is a global company that strives to develop and market generic and specialty drugs in multiple dosage forms for a wide range of diseases.The generic had received $130 million of global sales before 2018, an 8% increase.In August 2018, amnesal signed a 10-year license and supply agreement with Jerome Stevens for their levothyroxine sodium tablets and will be effective in the first half of 19 years.

Generic drug revenue: $1.55 billion
Total number of employees: 10416
Founding year: 1895
Headquarters: butterfelber, Germany
Market capitalization: $574 million

      
XetraStock Exchange: xetra, Germany
STADA is an international pharmaceutical company focused on generic and brand-name products.Its brand combination includes over-the-counter (OTC), prescription (Rx), and specific over-the-counter (Otx) products.Naxolone (tilidine naloxone), a generic drug for pain, has generated US $420 million sales worldwide, a 4% increase from 2018.In 2018, its generic business contributed 59% of sales.

Generic drug revenue: $1.69 billion
Total number of employees: 100000
Founding year: 1973
Headquarters: Paris, France
Market capitalization: $111.10 billion
  
SES: Pan European Exchange
Sanofi, a leading healthcare company worldwide, is committed to meeting patients' needs and is engaged in research, development, manufacturing and marketing of therapeutic solutions.The company focuses on neighborhoods of rare diseases, multiple sclerosis, immunology, rare blood disorders, oncology, diabetes, cardiovascular, and others, with established pharmaceutical pipelines featuring prescription products, generics, health care, and vaccines.Sanofi completed a transaction to sell its European generic business zentiva to advance international in September 2018.In addition, Sanofi released authorized generics of the tablet and particulate agent renvela (sevelamer carbonate) on the US market in 2017 and 2018, respectively.

Generic drug revenue: $1.70 billion
Total number of employees: 3131
Established: 1929
Headquarters: Osaka, Japan
Market capitalization: $23200 million

Stock Exchange: Tokyo Stock Institute
Sawai Pharma is a general-purpose pharmaceutical company specializing in a variety of therapeutic areas, such as cardiovascular drugs, lipid-lowering drugs, diabetes drugs, anticancer drugs and OTC drugs. In December 2018, Sawai launched six generic products with 14 advantages, which are mirtazapine tablet 15/30 mg, Atomoxetine capsule 5/10/25/40 mg, Toaraset (Ammonol Trimendol), ropinirone extended-release tablet 2/8 mg, Frewell (compound norethindrone), and capecitabine 300 mg. In addition, the company retains 310 products, with a cumulative 756 application advantages.

Generic drug revenue: $1.73 billion
Total number of employees: 26000
Founding year: 1935
Headquarters: Mumbai, India
Market capitalization: $5.29 billion
        
Stock Exchange: NSE, India
Cipla is the leading pharmaceutical company worldwide and ranks tenth among U.S. companies.Cipla is a leading generic drug company with a major focus on heart disease, oncology and diabetes.Cipla's isoproterenol (isuprel, isoproterenol hydrochloride) is a generic drug administered by intravenous, intravenous, SC, and intracardiac routes for the treatment of bradycardia, heart block, and rarely asthma.In 2018, the company launched 15 nonproprietary products and filed 15 nonproprietary internal submissions to the two nonproprietary authorized products.

Generic drug revenue: $1.77 billion
Total number of employees: 21966
Founding year: 1984
Headquarters: Ghana, Telan, India
Market capitalization: $6.32 billion     

Stock Exchange: NSE, India
Dr. Reddy's laboratory company is a global pharmaceutical company in three parts, R & D & API, global generic and patented medicines.The company focuses on gastrointestinal, cardiovascular, diabetes, oncology, pain and anti infection.In 2018, the company submitted 20 generic drug applications to the US FDA in addition to 110 generic drug applications pending approval, including 107 generic and 3 innovative drug applications under the 505b2 provision.

Generic drug revenue: $2.01 billion
Total number of employees: 8400
Founding year: 1978
Headquarters: London, UK
Market capitalization: $5.80 billion
      
SSX: London Stock Exchange
Hikma is a global pharmaceutical company focused on the development and marketing of non patented, brand-name products and injectable anti infectives, cardiovascular, central nervous system, diabetes (including oncology), pain management and respiratory.As of 2017, the company's generic drug plates have achieved 13% growth.The company launched over 90 products in 2018.In addition, in 2018, the company received food and Drug Administration approval for ritonavir tablets (U.S. Pharmacopeia standard), a 100 mg ritonavir tablet combined with antiretroviral drugs, for the treatment of human immunodeficiency virus infection.

Generic drug revenue: $2.25 billion
Total number of employees: 20000
Founding year: 1968
Headquarters: Mumbai, India
Market capitalization: $4.82 billion

Stock Exchange: NSE, India
Lupin is a pharmaceutical enterprise that has developed and supplied a wide range of generic drug formulations, biosimilar products, and drug substances worldwide,.Based on India's global revenue, the company ranks third in the pharmaceutical industry and sixth in Japan.Focusing on diverse therapeutic areas such as cardiovascular, diabetes, asthma, pediatrics, central nervous system, gastrointestinal, anti infective and NSAIDs, the company is leading the world in the anti TB field.

Generic Revenue: $2.83 billion
Total staff: 22000
Founding year: 1986
Headquarters: trengandhi, India
Market capitalization: $5.16 billion
 
Stock Exchange: NSE, India
Aurobindo Pharm is the world's leading manufacturer of generic and active pharmaceutical ingredients.The companies focus on therapeutic / pharmaceutical areas including antibiotics, antiretroviral drugs, CVs, CNS, systemic Gastroenterology, anti allergy, anti diabetes and other therapeutic areas.In 2018, Aurobindo acquired Apotex's operations in Poland, the Czech Republic, the Netherlands, Spain, and Belgium to enhance its penetration capacity into the European generic market.

Generic Revenue: 30.04
Total number of employees: 112658
Founding year: 1996
Headquarters: bad Homburg, Germany
Market capitalization: $25.03 billion
   
Stock Exchange: xetra, Germany
Fresenius kabi is a global healthcare company that develops and delivers products and services such as dialysis, non patented and intravenous drugs, biosimilars, medical devices in addition to infusion and nutrition therapy.Fesson's portfolio has approximately 90 + general anesthetics, analgesics, anti infectives and drugs administered intravenously to treat a wide range of ailments.In 2018, the company's total sales of non patented products increased by 5%.

Generic drug revenue: $4.10 billion
Total number of employees: 32000
Founding year: 1983
Headquarters: Mumbai, India
Market capitalization: $14.37 billion

SEC: Mumbai stock exchange
Indian solar pharmaceuticals is the fourth largest generic drug company in the world and the largest in India.In 2018, the company launched metformin hydrochloride (glumetza 500 mg, 1000 mg) extended release tablets in the United States.In August 2018, the company also received US FDA approval for cequa (cyclosporine ophthalmic solution, 0.09%).There are 118 andas and 8 NDAs pending US FDA approval from the Indian sun pharmaceutical industry.

Generic drug revenue: $5.21 billion
Total number of employees: 92400
Founding year: 1849
Headquarters: New York, USA
Market capitalization: $206.3 billion

ST: New York Stock Exchange
Pfizer is a research-based global biopharmaceutical company with a portfolio of products related to internal medicine, vaccines, oncology, inflammation and immunology, rare diseases, and everyday health products.
Pfizer's non patented business unit has a non patented brand-name and non patented product business located in China and includes 20 brands of non patented solid oral agents as well as certain non patented products.In 2018, Pfizer targeted sulperazon (sulbactam sodium / cefoperazone sodium) for urinary tract infection, generating $610 million sales revenue worldwide.

Generic drug revenue: $8.42 billion
Total number of employees: 15000
Founding year: 1886
Headquarters: holzkischen, Germany
Market capitalization: $46 billion   

Stock exchanges: Na
Sandoz, a division of Novartis pharmaceuticals, is leading the world in the development, production, and marketing of finished dosage form drugs as well as intermediate products including active pharmaceutical ingredients.The company is divided into three sectors globally, retail generic, anti infective and biopharmaceutical.Sandoz focuses on the treatment of cardiovascular disease, central nervous system disease, skin disease, gastrointestinal hormonal disease, metabolism, tumors, ocular pain, and respiratory disease.In addition, in 2018, Novartis agreed to sell a portion of the US portfolio of products to arabindo pharmaceuticals, India, specifically Sandoz's dermatology medicines and oral generic solid medicines business.

Generic drug revenue: $9.67 billion
Total number of employees: 42535
Founding year: 1944
Headquarters: pektikwa, Israel
Market capitalization: $31.77 billion     

Stock Exchange:New York Stock Exchange
Teva is a global pharmaceutical company leading the generic sector with a portfolio of over 35000 products in each therapeutic area.The manufactured products cover a wide range of dosage forms including tablets, capsules, injections, inhalants, liquids, ointments and creams.In 2018, Teva's generic drug, Copaxone (glatiramer acetate, IV), generated $2.36 billion in sales for the treatment of relapsing multiple sclerosis (MS), relapsing disease, and active secondary progressive disease in adults.

Generic drug revenue: $11.43 billion
Total number of employees: 35000
Established year: 1961
Headquarters: Pennsylvania, USA
Market capitalization: $11.47 billion

Stock Exchange: nadak
McLean is a global pharmaceutical company dedicated to the production of prescription generics, brand-name generics, including biosimilars, and over-the-counter drugs for the treatment of several diseases.The market for generic drugs exhibits a 4% decrease compared to 2017.The company launched more than 10 compound generics and biosimilars such as bivalirudin (Angiomax), tadalafil (adcirca), davaropyridine (ampyra), and mesalazine with straight intestinal plug (Allergan's canasa recombinant supplementary material) in 2018.More recently, in July 2019, Pfizer announced that it merged mCherry with Pfizer's own patent expiry brand and generic business unit, ponatinib, to create a new global pharmaceutical company.

Last:没有了
Next:Ranking world pharmaceutical companies at top1000 by 2020